Molecular and phenotypic determinants of the response to desmopressin in adult patients with mild hemophilia A

What Was Tested

Researchers studied Vasopressin and Desmopressin in this clinical trial publication.

The researchers prospectively assessed the molecular and phenotypic determinants of the biologic response to desmopressin in a cohort of 50 patients with mild hemophilia A.

Why It Was Studied

The relationship of the biologic response to desmopressin with the F8 mutation and physiological characteristics has been poorly investigated in patients with mild hemophilia A.

Who Took Part

The study group was 50 patients.

PubMed indexes the participants as young adults, adults, middle-aged adults and older adults.

How the Study Was Run

Up to 24 h after desmopressin, blood samples were serially obtained and factor (F)VIII and von Willebrand factor (VWF) measured.

The promoter region, all exons and exon-intron boundaries of the F8 gene were screened using denaturing high-performance liquid chromatography (DHPLC).

Direct sequencing was done when DHPLC screening was normal.

Genomic DNA was also sequenced for exons 18-21, 24 and 27 of VWF.

What Was Measured

The subject headings attached to it are Cohort Studies, Deamino Arginine Vasopressin, Factor VIII, Gene Components, Hemophilia A, Mutation and Phenotype.

What This Means in Plain Language

This is a clinical trial of Vasopressin and Desmopressin in 50 patients.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2009 (Journal of thrombosis and haemostasis : JTH), a journal based in England.

More context: the Vasopressin compound page and the Desmopressin compound page, all human trials.